In line with this finding we observed a loss of intratumoral CD4+ and CD8+ T cells upon RT, however this was restored upon treatment with mmHERA-CD40L (Figure 6D), suggesting that mmHERA-CD40L could counteract the negative immunosuppressive impact of RT and further enhance anti-tumor responses, which is in line previous data depicted in Figure 4. This evidence concerns the gene CD8A and neoplasm.